Harmony Biosciences says its flagship narcolepsy drug is on track to hit a major milestone, writes John George for The Philadelphia Business Journal.
The Plymouth Meeting business expects Wakix to surpass $1 billion in annual revenue this year. The drug treats excessive daytime sleepiness and cataplexy in patients with narcolepsy. It generated $868 million in sales last year. Harmony is forecasting 2026 Wakix revenue between $1 billion and $1.04 billion, representing growth of up to 20 percent. The company also reported net income of $136.2 million through the first nine months of 2025, signaling continued financial strength.
CEO Jeffrey M. Dayno said the company is entering its next phase of growth with strong momentum, driven in part by work on next-generation formulations of pitolisant, Wakix’s active ingredient. Harmony believes these advancements could extend the product’s lifecycle and support expansion for decades to come.
Beyond Wakix, Harmony’s pipeline includes pitolisant-HD and experimental treatments for rare forms of epilepsy, including Dravet syndrome and Lennox-Gastaut syndrome. The company also acknowledged recent setbacks, including an FDA rejection for Wakix’s use in idiopathic hypersomnia.
Despite some challenges, Harmony said it remains a profitable, self-funding biotech with plans to continue building out its pipeline and commercial portfolio.
To learn more about Plymouth Meeting’s Harmony Biosciences and its outlook and product pipeline, visit The Philadelphia Business Journal.
Editor’s Note: This post was originally published on MONTCO Today in January 2026.
